U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
HKEX’s Permissive IPO Rules Could Open Opportunities for Korea to Strengthen Its Position in International Listings 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
SAN DIEGO, April 27, 2017 -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the first quarter ended March 31, 2017, after the market close on Thursday, May 4, 2017. Conatus will host a conference call and audio webcast at 4:30 p.m. Eastern Time on Thursday, May 4, 2017, to discuss the financial results and provide a corporate update.
To access the conference call, please dial 877-312-5857 (domestic) or 970-315-0455 (international) at least five minutes prior to the start time and refer to conference ID 10334037. A live and archived audio webcast of the call will also be available in the Investors section of the Conatus website at www.conatuspharma.com.
About Conatus Pharmaceuticals
Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Conatus believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the disease progression across the spectrum of liver disease. For additional information, please visit www.conatuspharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding emricasan’s potential to interrupt the disease progression across the spectrum of liver disease. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those risks described in the company’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Alan Engbring Conatus Pharmaceuticals Inc. (858) 376-2637 [email protected]
